Skip to main content
Top
Published in: Rheumatology International 3/2008

01-01-2008 | Case Report

Clinical characteristics of lupus myocarditis in Korea

Authors: Jae-Wook Chung, Dai-Yeol Joe, Han-Jung Park, Hyoun-Ah Kim, Hae-Sim Park, Chang-Hee Suh

Published in: Rheumatology International | Issue 3/2008

Login to get access

Abstract

Clinically important myocarditis is an unusual feature in systemic lupus erythematosus (SLE). We describe the clinical characteristics, management and outcomes of five SLE patients who developed severe left ventricular dysfunction. Four patients were female with mean age of 36.4 years. Three patients had both lupus myocarditis and lupus nephritis. Four patients had raised anti-dsDNA antibody titer and low complement level and two patients had positive IgG anticardiolipin antibody. Three patients were treated by high-dose corticosteroids, one patient by intravenous pulse methylprednisolone, and one patient by intravenous immunoglobulin and pulse cyclophosphamide with high dose corticosteroids. Left ventricular function improved markedly in four patients and all of them had no recurrence of lupus myocarditis up to follow-up of 33 months. However, one patient, who showed no improvement of left ventricular function, was expired due to sudden cardiac arrest. Lupus myocarditis should be treated by immunosuppressive therapy with high-dose corticosteroids and mostly the prognosis might be good with early treatment.
Literature
1.
go back to reference D’Cruz D, Khamashta M, Huges GRV (2001) Cardiovascular manifestation of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematous. Lippincott Williams and Wilkins, Philadelphia pp 645 D’Cruz D, Khamashta M, Huges GRV (2001) Cardiovascular manifestation of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematous. Lippincott Williams and Wilkins, Philadelphia pp 645
2.
go back to reference Kao AH, Manzi S (2002) How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 16:211–227PubMedCrossRef Kao AH, Manzi S (2002) How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 16:211–227PubMedCrossRef
3.
4.
go back to reference Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284PubMedCrossRef Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284PubMedCrossRef
5.
go back to reference Sasson Z, Rasooly Y, Chow CW, Marshall S, Urowitz MB (1992) Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol 69:1629–1634PubMedCrossRef Sasson Z, Rasooly Y, Chow CW, Marshall S, Urowitz MB (1992) Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol 69:1629–1634PubMedCrossRef
6.
go back to reference Cervera R, Font J, Pare C et al (1992) Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 51:156–159PubMed Cervera R, Font J, Pare C et al (1992) Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 51:156–159PubMed
7.
go back to reference Doherty NE, Siegel RJ (1985) Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 110:1257–1265PubMedCrossRef Doherty NE, Siegel RJ (1985) Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 110:1257–1265PubMedCrossRef
8.
9.
go back to reference Murphy JG, Franz RP (2003) Endomyocardial biopsy in myocarditis. In: Cooper LT (Ed) Myocarditis: from bench to bedside. Humana, Totowa Murphy JG, Franz RP (2003) Endomyocardial biopsy in myocarditis. In: Cooper LT (Ed) Myocarditis: from bench to bedside. Humana, Totowa
10.
go back to reference Noutsias M, Pauschinger M, Poller WC, Schultheiss HP, Kuhl U (2003) Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Fail Monit 3:127–135PubMed Noutsias M, Pauschinger M, Poller WC, Schultheiss HP, Kuhl U (2003) Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Fail Monit 3:127–135PubMed
11.
go back to reference Biadani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69:849–858CrossRef Biadani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69:849–858CrossRef
12.
go back to reference Logar D, Kveder T, Rozman B, Dovovisek J (1990) Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 49:627–629PubMedCrossRef Logar D, Kveder T, Rozman B, Dovovisek J (1990) Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 49:627–629PubMedCrossRef
13.
go back to reference Leung WH, Wong KL, Lau CP, Wong CK, Liu HW (1990) Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89:411–419PubMedCrossRef Leung WH, Wong KL, Lau CP, Wong CK, Liu HW (1990) Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89:411–419PubMedCrossRef
14.
go back to reference Comin-Colet J, Saches-Corral MA, Alegre-Sancho JJ, Valverde J, Lopez-Gomez D, Sabate X et al (2001) Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. Lupus 10:59–62PubMedCrossRef Comin-Colet J, Saches-Corral MA, Alegre-Sancho JJ, Valverde J, Lopez-Gomez D, Sabate X et al (2001) Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. Lupus 10:59–62PubMedCrossRef
15.
go back to reference Law WG, Thong BY, Lian TY, Kong KO, Chng HH (2005) Acute lupus myocarditis: clinical features and outcome of an oriental series. Lupus 14:827–831PubMedCrossRef Law WG, Thong BY, Lian TY, Kong KO, Chng HH (2005) Acute lupus myocarditis: clinical features and outcome of an oriental series. Lupus 14:827–831PubMedCrossRef
16.
go back to reference Mason JW, O’Connel JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) For the myocarditis treatment trial investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Eng J Med 333:269–275CrossRef Mason JW, O’Connel JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) For the myocarditis treatment trial investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Eng J Med 333:269–275CrossRef
17.
go back to reference McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarcznk T, Kessler P, Mann DL, Feldman AM (2001) Controlled trial of intravenous immunoglobulin in recent-onset dialted cardiomyopathy. Circulation 103:2254–2259PubMed McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarcznk T, Kessler P, Mann DL, Feldman AM (2001) Controlled trial of intravenous immunoglobulin in recent-onset dialted cardiomyopathy. Circulation 103:2254–2259PubMed
18.
go back to reference Frustaci A, Gentiloni N, Caldarulo M (1996) Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. Chest 109:282–284PubMed Frustaci A, Gentiloni N, Caldarulo M (1996) Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. Chest 109:282–284PubMed
19.
go back to reference Chan YK, Li EK, Tam LS, Chow LT, Ng HK (2003) Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Scand J Rheumatol 32:306–308PubMedCrossRef Chan YK, Li EK, Tam LS, Chow LT, Ng HK (2003) Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Scand J Rheumatol 32:306–308PubMedCrossRef
20.
go back to reference Naarendorp M, Kerr LD, Khan AS, Ornstein MH (1999) Dramatic improvement of left ventricular function after cytotoxic therapy in lupus patients with acute cardiomyopathy: report of six cases. J Rheumatol 26:2257–2260PubMed Naarendorp M, Kerr LD, Khan AS, Ornstein MH (1999) Dramatic improvement of left ventricular function after cytotoxic therapy in lupus patients with acute cardiomyopathy: report of six cases. J Rheumatol 26:2257–2260PubMed
21.
go back to reference Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238–240PubMedCrossRef Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238–240PubMedCrossRef
22.
go back to reference Jacques E, Sophie R, Patrick A, Didier C, Xavier M (2004) Specific cardiomyopathy in lupus patients: report of three cases. Joint Bone Spine 71:66–69CrossRef Jacques E, Sophie R, Patrick A, Didier C, Xavier M (2004) Specific cardiomyopathy in lupus patients: report of three cases. Joint Bone Spine 71:66–69CrossRef
23.
go back to reference Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri MA (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14:683–686PubMedCrossRef Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri MA (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14:683–686PubMedCrossRef
24.
go back to reference Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G et al (2004) Prolongation of the corrected QT intervals in adult patients with anti-Ro/SSA positive connective tissue diseases. Arthritis Rheum 50:1248–1252PubMedCrossRef Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G et al (2004) Prolongation of the corrected QT intervals in adult patients with anti-Ro/SSA positive connective tissue diseases. Arthritis Rheum 50:1248–1252PubMedCrossRef
Metadata
Title
Clinical characteristics of lupus myocarditis in Korea
Authors
Jae-Wook Chung
Dai-Yeol Joe
Han-Jung Park
Hyoun-Ah Kim
Hae-Sim Park
Chang-Hee Suh
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0414-6

Other articles of this Issue 3/2008

Rheumatology International 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.